Leo I Gordon

32PUBLICATIONS
104CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Applied statisticsCancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Jun 04, 2026
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study.

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

|Jul 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Nicole J Altomare, Megan M Herr, Nisha M Nair

|Jul 24, 2025
Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.

Oluwatobi Odetola, Shuo Ma, Jane Winter

|May 30, 2025
CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis.

Sophia M Lamperis, Kaylin M McMahon, Andrea E Calvert

Pageof 6

Frequent Collaborators

17 joint publications

Reem Karmali

11 joint publications

Shuo Ma

8 joint publications

Thomas Ollila

8 joint publications

Narendranath Epperla